European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment

Cancer Treatment Reviews

Volumn 32, Issue SUPPL. 2, 2006, Pages S5-

  Repetto, Lazzaro ^a   Moeremans, Karen ^b   Annemans, Lieven ^b,c  

^a INRCA   (Italy)

^b IQVIA   (United States)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Cancer patients; Chemotherapy induced anaemia; Erythropoietin stimulating agents; European guidelines; Health economics

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECONOMIC ASPECT; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH SURVEY; HEMOGLOBIN DETERMINATION; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; IRON THERAPY; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; SYMPTOM; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; UNITED STATES;

EID: 33646867049     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.04.007     Document Type: Article

References (16)

1. Groopman J.E., and Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91 (1999) 1616-1634
2. Vansteenkiste J., Pirker R., Massuti B., Barata F., Font A., Fiegl M., et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94 (2002) 1211-1220
3. Ludwig H., Van B.S., Barrett-Lee P., Birgegard G., Bokemeyer C., Gascon P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40 (2004) 2293-2306
4. Rizzo J.D., Lichtin A.E., Woolf S.H., Seidenfeld J., Bennett C.L., Cella D., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20 (2002) 4083-4107
5. Sabbatini P. Clinical practice guidelines in oncology: cancer and treatment-related anemia. National Comprehensive Cancer Network; 2004.
6. Rizzo J.D., Lichtin A.E., Woolf S.H., Seidenfeld J., Bennett C.L., Cella D., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100 (2002) 2303-2320
7. Bokemeyer C., Aapro M.S., Courdi A., Foubert J., Link H., Osterborg A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40 (2004) 2201-2216
8. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996;14:671-9.
9. ® summary of product characteristics. Available from: www.emea.eu.int/humandocs/PDFs/EPAR/aranesp/H-332-PI-en.pdf [accessed October 2005].
10. Roche Registration Ltd. NeoRecormon Summary of Product Characteristics; 2005.
11. Canon J.L., Vansteenkiste J., Bodoky G., Mateos M., Bastit L., Ferreira I., et al. Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy. J Clin Oncol 23 (2005) 799
12. Glaspy J., Henry D., Patel R., Tchekmedyian S., Applebaum S., Berdeaux D., et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 41 (2005) 1140-1149
13. Berndt E., Crown W., Kallich J., Long S., Song X., and Lyman G.H. The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics 23 (2005) 183-192
14. Lyman G.H., Berndt E.R., Kallich J.D., Erder M.H., Crown W.H., Long S.R., et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 8 (2005) 149-156
15. Cremieux P.Y., Finkelstein S.N., Berndt E.R., Crawford J., and Slavin M.B. Cost effectiveness, quality-adjusted life-years and supportive care Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 16 (1999) 459-472
16. Martin S.C., Gagnon D.D., Zhang L., Bokemeyer C., Van Marwijk K.M., and van Hout H.B. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. Pharmacoeconomics 21 (2003) 1153-1169